Publications de Alan Nicolas Thierry Guichard

Trajectories of macrophage ontogeny and reprogramming in cancer

Michele De Palma, Céline Wyser Rmili, Gael Luis Boivin, Alan Nicolas Thierry Guichard, Nahal Mansouri

Tumor-associated macrophages (TAMs) often manifest immunosuppressive and tumor-promoting phenotypes contributing to immunotherapy resistance. Dicer1 inactivation in TAMs (DKO) prompts their immunostimulatory activation, enabling effective immunotherapy in ...

2025

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Michele De Palma, Bruno Torchia, Alan Nicolas Thierry Guichard, Yahya Mohammadzadeh, Ali Ghasemi, Nahal Mansouri

Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation, trafficking and function. Monocyte-derived DCs pulsed with tumor antigens have been tested extensively for therapeutic vaccination in cancer, with mixed clinical re ...

Nature Portfolio2023

Determinants of tumor resistance to anti-angiogenic immunotherapy in mouse models of Kras-mutant NSCLC

Ioanna Keklikoglou, Sina Nassiri, Etienne Meylan, Michele De Palma, Ece Kadioglu, Chiara Cianciaruso, Bruno Torchia, Alan Nicolas Thierry Guichard, Amaia Martinez Usatorre

AMER ASSOC CANCER RESEARCH2021

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Ioanna Keklikoglou, Nadine Fournier, Sina Nassiri, Etienne Meylan, Michele De Palma, Ece Kadioglu, Chiara Cianciaruso, Bruno Torchia, Gael Luis Boivin, Alan Nicolas Thierry Guichard, Amaia Martinez Usatorre

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of nonsmall cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic d ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Michele De Palma, Nicolo Rigamonti, Daniela Pais Ferreira, Alan Nicolas Thierry Guichard

Cancer immunotherapies are increasingly combined with targeted therapies to improve therapeutic outcomes. We show that combination of agonistic anti-CD40 with antiangiogenic antibodies targeting 2 proangiogenic factors, vascular endothelial growth factor A ...

2020

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Matthias Lütolf, Mauro Delorenzi, Laureline Wetterwald, Sina Nassiri, Michele De Palma, Mario Leonardo Squadrito, Nikolche Gjorevski, Alan Nicolas Thierry Guichard, Simone Ragusa, Borja Prat Luri

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential respon ...

2020

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

Ioanna Keklikoglou, Esra Güç, Michele De Palma, Mario Leonardo Squadrito, Antonino Cassarà, Chiara Cianciaruso, Alan Nicolas Thierry Guichard

Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can ...

2019